Signos

Signos is the first FDA-cleared medical software device focused on obesity, metabolic dysfunction and weight management. Its personalized AI is built on a continuous glucose monitoring infrastructure, using Dexcom’s over-the-counter CGM. The AI reads each member’s metabolism around the clock and guides the small daily behavior changes that add up to lasting weight loss.

The results hold up against medication. A peer-reviewed study of more than 3,000 adults found about 6% average weight loss at six months. That matches the average that similar real-world GLP-1 studies reported at 12 months.

For employers, Signos can be a lower-cost first line of defense for appropriate populations. It can also complement GLP-1 therapy, supporting appropriate use and more durable outcomes.